The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted ...
The Food and Drug Administration on Thursday approved Amgen's treatment for patients with the most deadly form of lung cancer ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
The U.S. Food and Drug Administration on Monday approved Biocon unit's biosimilar to Regeneron Pharmaceuticals' blockbuster ...
Schedule one drugs, such as heroin, are considered highly addictive with no medical benefits, while schedule three drugs are ...
Today, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the ...
The Food and Drug Administration last week approved an innovative new treatment for patients with a form of lung cancer. It ...
The Food and Drug Administration approved Imdelltra (tarlatamab) for the treatment of patients with advanced small cell lung ...
A team at King’s College London has developed a “drug delivery cage” that can be filled with chemotherapy drugs.
Tarlatamab, a bispecific T-cell engager, was approved by the FDA for adults with extensive-stage small cell lung cancer.